ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,737 | -9.2% | 100,839 | +2.8% | 0.02% | -10.0% |
| Q2 2023 | $3,015 | +1.3% | 98,077 | +18.8% | 0.02% | 0.0% |
| Q1 2023 | $2,975 | +95.6% | 82,570 | +114.5% | 0.02% | +81.8% |
| Q4 2022 | $1,521 | -99.9% | 38,487 | -46.4% | 0.01% | -47.6% |
| Q3 2022 | $2,885,000 | -7.4% | 71,796 | -3.1% | 0.02% | 0.0% |
| Q2 2022 | $3,116,000 | -33.8% | 74,110 | -38.6% | 0.02% | -12.5% |
| Q1 2022 | $4,706,000 | +78.3% | 120,798 | +82.4% | 0.02% | +100.0% |
| Q4 2021 | $2,639,000 | +159.5% | 66,212 | +135.2% | 0.01% | +140.0% |
| Q3 2021 | $1,017,000 | +8.0% | 28,147 | +22.4% | 0.01% | 0.0% |
| Q2 2021 | $942,000 | -41.5% | 22,988 | -37.8% | 0.01% | -44.4% |
| Q1 2021 | $1,611,000 | +209.8% | 36,929 | +255.3% | 0.01% | +200.0% |
| Q4 2020 | $520,000 | +114.0% | 10,394 | +107.9% | 0.00% | +50.0% |
| Q2 2020 | $243,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |